Beyond the Lab: Biomarkers Powering Tomorrow’s Therapies
5 August 2025
Shares
Biomarkers aren’t just supporting drug discovery – they’re driving it. From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
Biomarkers aren’t just influencing early drug development – they’re powering it forward. This expert-led report cuts through the noise to explore how biomarker science is shaping smarter trials, cleaner data and more targeted therapies. From discovery to diagnostics, psychiatry to oncology, it’s clear: biomarkers are delivering real impact where it counts.
What you’ll learn
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
- What goes wrong when biomarkers fail and how to design for clinical success
Trends we explore
- The rise of biomarker-led clinical strategy
- Better tools for real-time, in-human decision-making
- Assay sensitivity and standardisation across global trial networks
Featuring expert insights from:
- Dr Cyril Clarke, VP, ICON Biotech
- Dr Adam Savitz, Chief Medical Officer, Alto Neuroscience
- Gayle Marshall, Biomarker Lead, Medicines Discovery Catapult
- Dr Andrew Roche, VP, ICON Laboratory Solutions
- Dr Jessica Baumann, Medical Director, Companion Diagnostics & Advanced Assays, Leica Biosystems
Whether you’re building biomarker strategies or solving translational roadblocks, this report shares expert guidance to help you go from discovery to application – faster, and with more clarity.
Explore how biomarkers are shaping early drug development – from discovery to clinical decision-making. Access the full report >>
Reduce preclinical failures with smarter off-target profiling
24 September 2025 | 15:00PM BST | FREE Webinar
Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.
What you’ll learn:
- Approaches for prioritizing follow-up studies and refining risk mitigation strategies
- How to interpret hit profiles from binding and functional assays
- Strategies for identifying organ systems at risk based on target activity modulation
- How to use visualization tools to assess safety margins and compare compound profiles
Register Now – It’s Free!
This report is sponsored by:
